PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 593
- Registration Number
- NCT01458574
- Locations
- πΊπΈ
Springhill Memorial Hospital (Endoscopy Only), Mobile, Alabama, United States
πΊπΈHope Square Surgical Center, Rancho Mirage, California, United States
πΊπΈGI Consultants, Atlanta, Georgia, United States
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 547
- Registration Number
- NCT01458951
- Locations
- π΅π±
Centrum Endoskopii Zabiegowej, Poradnia Chorob Jelitowych,, Bydgoszcz, Kujawsko-pomorskie, Poland
π΅π±H-T Centrum Medyczne sp. z o.o. sp. komandytowa, Tychy, Slaskie, Poland
πΊπΈAtlanta Center for Gastroenterology, P.C., Decatur, Georgia, United States
Ceftaroline China Pharmacokinetics Study
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT01458743
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
- Conditions
- Smoking Cessation
- Interventions
- First Posted Date
- 2011-10-21
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8144
- Registration Number
- NCT01456936
- Locations
- πΊπΈ
Pharmacology Research Institute, Newport Beach, California, United States
πΊπΈBelmont Center for Comprehensive Treatment, Philadelphia, Pennsylvania, United States
π¦π·Centro de Investigacion Clinica WM, Mataderos, Buenos Aires, Argentina
Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Ξ -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone
- Conditions
- Healthy
- Interventions
- Drug: ALO-02 (Oxycodone Naltrexone)
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT01456507
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Pharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate/325 mg Acetaminophen) Compared to the Reference Drug Norco
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT01456520
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104
- Conditions
- Healthy
- Interventions
- Drug: [14C]NXL104
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT01448395
- Locations
- π¬π§
Study site, Ruddington, Nottingham, United Kingdom
Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics
- Conditions
- Human Volunteers
- Interventions
- Drug: Simvastatin/PF-03882845
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT01445860
- Locations
- πΈπ¬
Pfizer Investigational Site, Singapore, Singapore
Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT01445873
Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition
- Conditions
- Migraine
- Interventions
- Drug: BMS-927711 (CGRP Antagonist)
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT01445067
- Locations
- πΊπΈ
California Clinical Trials Medical Group, Glendale, California, United States
πΊπΈCollaborative Neuroscience Network, Inc., Long Beach, California, United States
πΊπΈCommunity Research, Cincinnati, Ohio, United States